| References |
1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR. Global burden of disease of HIV-associated cryptococcalmeningitis: an updated analysis. Lancet Infect Dis. 2017;17:873-881. 2. Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61-79. 3. O'Halloran JA, Powderly WG, Spec A. Cryptococcosis today: it is not all about HIV infection. Curr Clin Microbiol Rep. 2017;4:88-95. 4. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, Henderson H, Kauffman CA, Haas DW, Saccente M, Hamill RJ, Holloway MS, Warren RM, Dismukes WE. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33:690-699. 5. Nguyen MH, Husain S, Clancy CJ, Peacock JE, Hung CC, Kontoyiannis DP, Morris AJ, Heath CH, Wagener M, Yu VL. Outcomes of central nervous system cryptococcus is vary with host immune function: results from a multi-center, prospective study. J Infect. 2010;61:419-426. 6. Kestelyn P, Taelman H, Bogaerts J, Kagame A, Abdel Aziz M, Batungwanayo J, Stevens AM, Van de Perre P. Ophthalmic manifestations of infections with Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;116:721-727. 7. Hester DE, Kylstra JA, Eifrig DE. Isolated ocular cryptococcosis in an immunocompetent patient. Ophthalmic Surg. 1992;23:129-131. 8. Amphornphruet A, Silpa-Archa S, Preble JM, Foster CS. Endogenous cryptococcal endophthalmitis in immunocompetent host: case report and review of multimodal imaging findings and treatment. Ocul Immunol Inflamm. 2018;26:518-522. 9. Stone SP, Bendig J, Hakim J, Kinnear PE, Azadian BS, Clifford-Rose F. Cryptococcal meningitis presenting as uveitis. Br J Ophthalmol. 1988;72:167-170. 10. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13:388-391. 11. Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA. Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg. 1997;91:44-49. 12. Lalloo D, Fisher D, Naraqi S, Laurenson I, Temu P, Sinha A, Saweri A, Mavo B. Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously healthy Melanesian adults in Papua New Guinea. Q J Med. 1994;87:343-349. 13. Moodley A, Rae W, Bhigjee A, Connolly C, Devparsad N, Michowicz A, Harrison T, Loyse A. Early clinical and subclinical visual evoked potential and Humphrey's visual field defects in cryptococcal meningitis. PLoS One. 2012;7:e52895. 14. Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore). 1993;72:207-224. 15. Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C, Musubire A, Rajasingham R, Williams DA, Thienemann F, Muzoora C, Meintjes G, Meya DB, Boulware DR. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014;59:1607-1614. 16. Khurana RN, Javaheri M, Rao N. Ophthalmic manifestations of immune reconstitution inflammatory syndrome associated with Cryptococcus neoformans. Ocul Immunol Inflamm. 2008;16:185-190. 17. Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA. The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg. 1997;91:50-52. 18. Anjum S, Dean O, Kosa P, Magone MT, King KA, Fitzgibbon E, Kim HJ, Zalewski C, Murphy E, Billioux BJ, Chisholm J, Brewer CC, Krieger C, Elsegeiny W, Scott TL, Wang J, Hunsberger S, Bennett JE, Nath A, Marr KA, Bielekova B, Wendler D, Hammoud DA, Williamson P. Outcomes in previously healthy cryptococcal meningoencephalitis patients treated with pulse-taper corticosteroids for post-infectious inflammatory syndrome. Clin Infect Dis. 2021;73:e2789-e2798. 19. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30:47-54. 20. Saijo T, Chen J, Chen SCA, Rosen LB, Yi J, Sorrell TC, Bennett JE, Holland SM, Browne SK, Kwon-Chung KJ. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio. 2014;5:e00912-e00914. |
